A RCT on the Preventive Effect of HFNC on Postoperative Pulmonary Complications in Patients With Gynecologic Neoplasms
Recruiting · NCT05526534 · Interventional (participants receive a specific treatment) · Lead sponsor: Sichuan Cancer Hospital and Research Institute
View the official record on ClinicalTrials.gov →Interventions studied
Nasal cannula oxygenheated humidified high flow nasal cannula oxygen therapy, HFNC
What this trial is about
Patients at high risk of post-operative pulmonary complications (PPC) will be screened out from gynecological tumor patients undergoing surgical treatment, and randomly assigned into the HFNC group and control group, which uses conventional nasal cannula oxygen therapy. The primary outcome is the incidence of PPC, including postoperative hypoxemia, atelectasis, pneumonia, etc. Secondary outcomes are the improvement of postoperative oxygenation, antibiotic use, length of hospital stay, adverse events related to oxygen therapy, etc.
Who can take part
Age range
18 Years to 90 Years
Sex
Female
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with gynecologic Neoplasms, including benign gynecologic tumors and malignant gynecologic tumors, who are 18 to 90 years old and are scheduled for surgical treatment in our center shall receive plain chest CT scan within 1 week before surgery, and the estimated surgical time shall be ≥2 hours, and at least one of the following conditions shall be met:
- Assess respiratory risk in surgical patients in Catalonia (ARRSPC) ≥45 points;
- BMI≥30;
- Moderate to severe asthma;
- Moderate to severe chronic obstructive pulmonary disease (COPD);
- Smoking history ≥20 packs/year
Exclusion criteria
- Patients with lung metastasis of malignant tumor or primary lung malignant tumor;
- previous lung surgery or radiotherapy;
- the surgery involved segmental bowel resection.
Where it is running
1 location listed.
- Sichuan Cancer Hospital and Research Institute - Chengdu, Sichuan, China